We recently published a list of 10 Stocks with Potential to Explode in 2025. In this article, we are going to take a look at ...

It's been nearly five years since Moderna (NASDAQ: MRNA) emerged as a biotech industry disruptor, with its COVID-19 vaccine ...

As we previously discussed, beginning in 2022, a series of patent infringement lawsuits were filed against Moderna and ...

Delving into the details, we found 40% of traders were bullish, while 50% showed bearish tendencies. Out of all the trades we ...

Moderna (NASDAQ:MRNA – Get Free Report) had its price objective lowered by analysts at JPMorgan Chase & Co. from $40.00 to ...

Moderna CEO Stéphane Bancel received an annual compensation package worth $19.87 million last year, the largest he’s ever ...

Shares of Moderna, Inc. (NASDAQ:MRNA – Get Free Report) have been assigned an average rating of “Hold” from the twenty-four ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Paula Newton speaks with co-founder and Chair of Moderna, Noubar Afeyan, about his hopes for the release of Ruben Vardanyan, ...

One of the most underappreciated applications of artificial intelligence in the corporate world involves its role in writing ...

Moderna Inc., a biotechnology and pharmaceutical company reorienting its business for a post-pandemic age, awarded almost $17 ...

Citi initiated coverage of Moderna (MRNA) with a Neutral rating and $40 price target Healthcare policy remains a key biopharma sector ...